

---

**Product Data Sheet**

---

Product Name: S-2E  
Cat. No.: GC67661

**Chemical Properties**

Cas. No. 155730-92-0

Formula  $C_{22}H_{25}NO_4$  M.Wt 367.44

Solubility Storage Store at  $-20^{\circ}C$

General tips For obtaining a higher solubility, please warm the tube at  $37^{\circ}C$  and shake it in the ultrasonic bath for a while. Stock solution can be stored below  $-20^{\circ}C$  for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure

**Background**

S-2E is an orally active and noncompetitive **HMG-CoA reductase** and **acetyl-CoA carboxylase** inhibitor. S-2E has an anti-hyperlipidemic action. S-2E has the potential for familial hypercholesterolemia and mixed hyperlipidemia research<sup>[1][2]</sup>.

In the liver, S-2E is converted into its active metabolite, S-2E-CoA. S-2E-CoA noncompetitively inhibits the enzymatic activities of both 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase and acetyl-CoA carboxylase at  $K_i=18.11 \mu M$  and  $K_i=69.2 \mu M$ , respectively<sup>[1]</sup>.

S-2E (3-30 mg/kg) given orally suppresses the secretion rate of very-low-density lipoprotein (VLDL)-cholesterol and triglyceride in Triton WR-1339-injected rats. Furthermore, S-2E lowers the blood total cholesterol and triglyceride levels simultaneously in Zucker fatty rats<sup>[1]</sup>.

[1]. Koichi Ohmori, et al. Anti-hyperlipidemic action of a newly synthesized benzoic acid derivative, S-2E. Eur J Pharmacol. 2003 Jun 13;471(1):69-76.

[2]. K Ohmori, et al. Effects of a novel antihyperlipidemic agent, S-2E, on the blood lipid abnormalities in homozygous WHHL rabbits. Metabolism. 2004 May;53(5):680-5.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA